A Dose Block-randomized, Double-blind, Placebo-controlled, Single Dose, Dose-escalation Study to Investigate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Tolvaptan in Healthy Korean Male Subjects Bipolar Disorder.
Phase of Trial: Phase I
Latest Information Update: 17 Sep 2016
At a glance
- Drugs Tolvaptan (Primary)
- Indications Heart failure
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Korea Otsuka International Asia Arab Co
- 29 Nov 2011 Results published in the Journal of Cardiovascular Pharmacology.
- 12 Mar 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 12 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.